Zealand Pharma Revenue vs. Book Value Per Share

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>ZP</div>
ZEAL -- Denmark Stock  

DKK 264.00  12.00  4.76%

The Drivers Module shows relationships between Zealand Pharma's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Zealand Pharma AS over time as well as its relative position and ranking within its peers. Check out Your Current Watchlist

Search Current Fundamental Trends

 
Refresh
Sales per Share is projected to rize to 1.46 this yearZealand Pharma Operating Income is quite stable at the moment as compared to the last year. The company current value of Operating Income is estimated at about 633.51 Million. Net Income Per Employee is projected to rize to about 3.8 M this year, although the value of Net Income will most likely fall to (508.2 M).

Zealand Pharma AS Book Value Per Share vs. Revenue Fundamental Analysis

Zealand Pharma AS is rated second in revenue category among related companies. It is rated second in book value per share category among related companies . The ratio of Revenue to Book Value Per Share for Zealand Pharma AS is about  1,301,424 . Zealand Pharma Revenues is quite stable at the moment as compared to the last year. The company current value of Revenues is estimated at about 42.96 Million
Zealand Pharma AS is rated second in revenue category among related companies. Market size based on revenue of Biotechnology industry is at this time estimated at about 85.92 Million. Zealand Pharma totals roughly 42.96 Million in revenue claiming about 50% of stocks in Biotechnology industry.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and is an essential item when evaluating financial statements of a company. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Zealand Pharma 
Revenue 
 = 
Money Received 
Discounts and Returns 
=
42.96 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Book Value per Share (B/S) is can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Zealand Pharma 
Book Value per Share 
 = 
Common Equity 
Average Shares 
=
33.01 
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Zealand Book Value Per Share Comparison

Zealand Fundamental Comparison

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page